Reply - 05/07/21
Doi : 10.1016/j.jaci.2021.03.040
Corinne Keet, MD, PhD a, b 
, Wayne Shreffler, MD, PhD c, Alkis Togias, MD d, Michael Pistiner, MD, MMSc c
, Wayne Shreffler, MD, PhD c, Alkis Togias, MD d, Michael Pistiner, MD, MMSc c a Division of Pediatric Allergy, Immunology and Rheumatology, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, Md
b Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md
c Division of Pediatric Allergy and Immunology, Department of Pediatrics, Mass General Hospital for Children, Harvard Medical School, Boston, Mass
d Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
Le texte complet de cet article est disponible en PDF.
| Dr Togias’ authorship of this report does not constitute endorsement by the US National Institute of Allergy and Infectious Diseases or any other US government agency. |
|
| This study was funded by the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (grant no. 1U01AI125290). This publication was made possible by the Johns Hopkins Institute for Clinical and Translational Research (ICTR), which is funded in part by the National Center for Advancing Translational Sciences (NCATS; grant no. UL1 TR003098), a component of the NIH, and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the Johns Hopkins ICTR, NCATS, or NIH. The project described was supported by grant number 1UL1TR002541-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources, the NCATS, or the NIH. |
|
| Disclosure of potential conflict of interest: C. Keet receives royalties from Up to Date. W. Shreffler has served on the Scientific Advisory Board of Aimmune Therapeutics, and as an advisor to Food Allergy Research & Education, Buhlmann Laboratories AG, and Sanofi Pasteur. A. Togias reports no relevant conflicts of interest. M. Pistiner has served as a consultant for AAFA, kaléo, and DBV Technologies; received funding from kaléo, DBV Technologies, and the National Peanut Board; and is cofounder of AllergyHome and Allergy Certified Training. |
© 2021
American Academy of Allergy, Asthma & Immunology. Tous droits réservés.
Vol 148 - N° 1
P. 275 - juillet 2021 Retour au numéro
Article précédent
- Shorter “time to peanut introduction” can prevent peanut allergy and avert false Ara h 2 screening results in infants
- Edward G.A. Iglesia, Edwin H. Kim
- Corrigenda
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?